Espinoza L R, Jara L J, Martinez-Osuna P, Silveira L H, Cuellar M L, Seleznick M
Department of Medicine, Louisiana State University School of Medicine, New Oreleans.
Lupus. 1993 Feb;2(1):9-14. doi: 10.1177/096120339300200103.
The effects of indomethacin on urinary protein excretion, levels of serum albumin and renal function were studied prospectively in six patients with systemic lupus erythematosus (SLE) and refractory nephrotic syndrome due to lupus nephritis. Two had membranoproliferative glomerulonephritis, two had diffuse proliferative glomerulonephritis, and one each had mesangioproliferative and membranous glomerulonephritis. All experienced a considerable reduction in urinary protein excretion and an increase in serum albumin. Indomethacin was discontinued in two patients because of side effects, and proteinuria recurred to pretreatment levels. The decrease of proteinuria continued during long-term treatment in three patients. Indomethacin did not cause a permanent decline in renal function. Our results suggest that therapy with indomethacin may be beneficial for the treatment of refractory nephrotic syndrome in selected SLE patients. However, because of potential side effects the administration of indomethacin should be monitored closely.
前瞻性地研究了吲哚美辛对6例系统性红斑狼疮（SLE）合并狼疮性肾炎所致难治性肾病综合征患者尿蛋白排泄、血清白蛋白水平和肾功能的影响。其中2例为膜增生性肾小球肾炎，2例为弥漫性增生性肾小球肾炎，1例为系膜增生性肾小球肾炎，1例为膜性肾小球肾炎。所有患者的尿蛋白排泄均显著减少，血清白蛋白增加。2例患者因副作用停用吲哚美辛，蛋白尿复发至治疗前水平。3例患者在长期治疗期间蛋白尿持续减少。吲哚美辛未导致肾功能永久性下降。我们的结果表明，吲哚美辛治疗可能对部分SLE患者难治性肾病综合征的治疗有益。然而，由于存在潜在副作用，应密切监测吲哚美辛的使用。
